the U.S. Department of Health and Human Services
HHS
the Food and Drug Administration
National Institutes of Health
Gilead
Medicare
Medicaid
The nonprofit Institute for Clinical and Economic Review
Remedsivir
NIH
Johns Hopkins University
the Emergency Use Authorization
EUA
trip."Gilead
JAMA Internal Medicine
COVID-19
Xavier Becerra
Jeff Landry
Remdesivir
Democrat
Republican
Americans
No matching tags
No matching tags
California
Louisiana
Alaska
Connecticut
Delaware
Hawaii
Idaho
Illinois
Iowa
Kansas
Maine
Maryland
Massachusetts
Michigan
Minnesota
Nebraska
Nevada
New Hampshire
New Mexico
New York
North Carolina
North Dakota
Ohio
Oregon
Pennsylvania
Rhode Island
South Dakota
Utah
Vermont
Virginia
Washington
the District of Columbia
American Samoa
Guam
No matching tags
A bipartisan coalition of attorneys general asked the U.S. Department of Health and Human Services on Tuesday to invoke a federal patent law to increase supply and lower prices of the COVID-19 drug remdesivir.The group, led by California Attorney General Xavier Becerra and Louisiana Attorney General Jeff Landry, said HHS, the Food and Drug Administration and National Institutes of Health should license Gilead Sciences’ antiviral to other manufacturers to ease potential shortages and lower the drug's price.Gilead charges $3,120 for a five-day course for patients with private insurance, Medicare or Medicaid.
As said here by